ALIM: Alimera Sciences, Inc. Stock

by  •  • Comments Off on ALIM: Alimera Sciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 292.85
Enterprise Value ($M) 347.97
Book Value ($M) 40.65
Book Value / Share 0.78
Price / Book 7.20
NCAV ($M) -57.36
NCAV / Share -1.09
Price / NCAV -5.11

Profitability (mra)
Return on Invested Capital (ROIC) -0.19
Return on Assets (ROA) -0.14
Return on Equity (ROE) -0.46

Liquidity (mrq)
Quick Ratio 2.51
Current Ratio 2.62

Balance Sheet (mrq) ($M)
Current Assets 54.47
Assets 152.49
Liabilities 111.83
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 80.75
Operating Income -1.93
Net Income -20.13
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -14.26
Cash from Investing -75.53
Cash from Financing 96.50

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
06-24 13D/A Caligan Partners LP 33.20 0.00
05-16 13D/A Velan Capital Investment Management LP 27.20 6.22
02-14 13G/A Lytton Laurence W 4.20 -26.78
02-13 13G/A HBM Healthcare Investments (Cayman) Ltd. 0.90 0.00
02-13 13G/A Stonepine Capital Management, LLC 9.99 -0.07
02-13 13G/A Altium Capital Management LP 5.00 -10.88
02-13 13G/A Boothbay Fund Management, Llc 6.10 -33.14
12-08 13G/A Morgan Stanley 1.80 37.52

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT P
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One)
2024-03-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)
2023-11-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPO
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-26 2,191 1,327,506 0.17
2024-07-25 14,558 196,118 7.42
2024-07-24 4,155 91,748 4.53
2024-07-23 961 57,447 1.67
2024-07-22 5,444 50,514 10.78

(click for more detail)

Similar Companies
ACRV – Acrivon Therapeutics, Inc. ADMA – ADMA Biologics, Inc.
AFMD – Affimed N.V. ALT – Altimmune, Inc.
ANIP – ANI Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Almira Sciences